Non-alcoholic fatty liver disease (NAFLD) is the most prevalent chronic liver disease and is
emerging as the leading cause of cirrhosis, liver transplantation and hepatocellular …

Non-alcoholic fatty liver disease (NAFLD) has emerged pandemically across the globe and
particularly affects patients with obesity and type 2 diabetes. NAFLD is a complex systemic …

To test the hypothesis that the gut microbiota of individuals with nonalcoholic fatty liver
disease (NAFLD) produce enough ethanol to be a driving force in the development and …

Nonalcoholic fatty liver disease (NAFLD), recently renamed metabolic-associated fatty liver
disease (MAFLD), is one of the most common causes of liver diseases worldwide. NAFLD is …

Metabolic disorders represent a growing worldwide health challenge due to their
dramatically increasing prevalence. The gut microbiota is a crucial actor that can interact …

The multimodal activities of farnesoid X receptor (FXR) agonists make this class an attractive
option to treat nonalcoholic steatohepatitis. The safety and efficacy of tropifexor, an FXR …

Importance No therapy has been shown to reduce the risk of serious adverse outcomes in
patients with nonalcoholic steatohepatitis (NASH). Objective To investigate the long-term …

Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease
worldwide. NAFLD begins as a relatively benign hepatic steatosis which can evolve to non …

Non-alcoholic fatty liver DISEASE (NAFLD) is the most common chronic liver disease in
Western countries and affects approximately 25% of the adult population. Since NAFLD is …

Background and Aims NAFLD is characterized by insulin resistance and dysregulated lipid
and glucose metabolism. Saroglitazar, a dual peroxisome proliferator activated receptor‐α/γ …